BioNTech Swings to Net Loss on Lower Covid Vaccine Sales
By Helena Smolak
BioNTech swung to a net loss in the first quarter, when revenue plummeted after a sharp decline in its Covid-19 vaccine sales.
The German biotechnology company, listed on the U.S. stock exchange, said Monday that it recorded a first-quarter net loss of 315.1 million euros ($339.2 million) compared with a net profit of EUR502.2 million in the same prior-year period.
First-quarter revenue came in at EUR187.6 million compared with EUR1.28 billion the year prior due to a sales decline of its Covid-19 vaccine Comirnaty.
BioNTech reiterated its full-year revenue outlook of between EUR2.5 billion and EUR3.1 billion, expecting to book approximately 90% of its full-year revenue in the last months of 2024.
"We aim to have 10 or more potentially registrational trials running by year-end 2024, which we believe will change the picture of the company going forward. Besides having a strong franchise in infectious diseases, we aim to have multiple oncology products reaching the market by 2026 onwards," Chief Financial Officer Jens Holstein said.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 06, 2024 07:27 ET (11:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending